Cat. No. | Product name | CAS No. |
DC11448 |
LOXO 195(Selitrectinib)
Featured
LOXO-195 is a next-generation TRK kinase (TKI) inhibitor, with IC50s of 0.6±0.1 nM, <2.5 nM for TRKA and TRKC respectively. |
2097002-61-2 |
DC8541 |
ORY-1001(Ladademstat)
Featured
ORY-1001 dihydrochloride (RG-6016, Ladademstat) is a highly potent, selective inhibitor of lysine-specific demethylase KDM1A (LSD1) with IC50 of 18 nM, displays high selectivity for KDM1A over other FAD-containing monoamine oxidases. |
1431303-72-8 |
DC10755 |
LSZ-102
Featured
LSZ102 is a potent, orally bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer. |
2135600-76-7 |
DC10987 |
LTX-315
This product is discontinued. LTX-315 (Oncopore) is a synthetic 9-mer anticancer peptide that preferentially permeabilizes mitochondrial membranes, thereby causing partially BAX/BAK1-regulated, caspase-independent necrosis. |
1345407-05-7 |
DC7456 |
LX1606 Hippurate
Featured
LX1606 is an orally bioavailable, small-molecule, tryptophan hydroxylase (TPH) inhibitor with potential antiserotonergic activity. |
1137608-69-5 |
DC10828 |
LXH254
Featured
LXH254 is a potent CRAF inhibitor extracted from patent WO2018051306A1, Compound A. LXH254 also is a potent BRAF inhibitor. |
1800398-38-2 |
DC6306 |
LY2157299(Galunisertib)
Featured
LY2157299 is a potent TGFβ receptor I (TβRI) inhibitor with IC50 of 56 nM. Phase 2. |
700874-72-2 |
DC8630 |
Ralimetinib 2MsOH(LY2228820)
Featured
LY2228820 is a novel and potent p38MAPK inhibitor (the IC50 for p38αMAPK and p38βMAPK were 7 nM and 3 nM, respectively). |
862507-23-1 |
DC10782 |
LY2510924
Featured
LY2510924 is an inhibitor of CXC chemokine receptor 4 (CXCR4), with potential antineoplastic activity. |
1088715-84-7 |
DC7943 |
LYS6K2(LY2584702) tosylate salt
Featured
LY-2584702 is an orally available inhibitor of p70S6K signaling; inhibits p70S6K and prevents phosphorylation of the S6 subunit of ribosomes. |
1082949-68-5 |
DC7103 |
LY2603618(IC-83)
Featured
LY2603618(IC-83) is a potent and selective small molecule inhibitor of Chk1 protein kinase activity in vitro (IC50=7 nM) and the first selective Chk1 inhibitor to enter clinical cancer trials. |
911222-45-2 |
DC7993 |
Prexasertib (LY2606368) 2HCl
Featured
LY2606368 2Hcl is a potent and selective ATP competitive inhibitor(IC50=1.5 nM in SW1990 cell) of the Chk1 protein kinase. |
1234015-54-3 |
DC10796 |
Prexasertib (LY2606368)
Featured
LY2606368 is a potent and selective ATP competitive inhibitor(IC50=1.5 nM in SW1990 cell) of the Chk1 protein kinase. |
1234015-52-1 |
DC7665 |
Gandotinib(LY2784544)
Featured
LY2784544 is a potent JAK2 inhibitor with IC50 of 3 nM, effective in JAK2V617F, 8- and 20-fold selective versus JAK1 and JAK3. Phase 2. |
1229236-86-5 |
DC7019 |
LY-2874455
Featured
LY2874455 is a novel and potent FGF/FGFR inhibitor. |
1254473-64-7 |
DC7191 |
LY-2940680(Taladegib)
Featured
LY2940680 binds to the Smoothened (Smo) receptor and potently inhibits Hedgehog (Hh) signaling. |
1258861-20-9 |
DC8344 |
LY3009120
Featured
LY3009120 is a potent and selective pan-RAF inhibitor with potential anticancer activity. |
1454682-72-4 |
DC10219 |
LY3023414
Featured
LY3023414 is an oral ATP competitive inhibitor of the class I PI3K isoforms, mTOR and DNA-PK. |
1386874-06-1 |
DC7776 |
LY-3039478
LY3039478 a orally bioavailable, novel small molecule Notch inhibitor with an IC50 of ~1nM in most of the tumor cell lines tested. |
1421438-81-4 |
DC10675 |
LY3200882
Featured
LY3200882 is a novel, highly selective TGFβRI small molecule inhibitor. |
1898283-02-7 |
DC10640 |
LY3214996
Featured
LY3214996 is a selective and novel ERK1/2 inhibitor with IC50 of 5 nM for both enzymes in biochemical assays. It potently inhibits cellular phospho-RSK1 in BRAF and RAS mutant cancer cell lines. |
1951483-29-6 |
DC12261 |
LY3295668 (AK-01)
LY3295668 is a potent, orally active and highly specific Aurora-A kinase inhibitor, with Ki values of 0.8 nM and 1038 nM for AurA and AurB, respectively. |
1919888-06-4 |